Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.79 |
| ▸ | PPARA | Q07869 | 4/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037316 | 0.92 | PPARG (0.80) | PPARGPPARAKDM4EMEN1KMT2A | |
| SCHEMBL7040522 | 0.90 | PPARG (0.82) | PPARGPPARAKDM4EMEN1KMT2A | |
| SCHEMBL7036649 | 0.89 | PPARG (0.80) | PPARGPPARAKDM4EMEN1KMT2A | |
| Lithium Ion SCHEMBL7036645 | 0.88 | PPARG (1.00) | PPARGPPARAKDM4EMEN1KMT2A | |
| SCHEMBL7039313 | 0.82 | PPARG (0.55) | PPARGPPARAMEN1KMT2ANPC1 | |
| SCHEMBL7039857 | 0.82 | PPARG (0.67) | PPARGPPARAKDM4EMEN1KMT2A | |
| SCHEMBL7037060 | 0.82 | PPARG (0.62) | PPARGPPARASMN1; SMN2ALDH1A1 | |
| SCHEMBL7037603 | 0.82 | PPARG (0.56) | PPARGPPARAMEN1KMT2ANPC1 | |
| SCHEMBL7039618 | 0.82 | PPARG (0.83) | PPARGPPARAKDM4EMEN1KMT2A | |
| SCHEMBL7034823 | 0.81 | PPARG (0.81) | PPARGPPARAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030082631-A1 | Compounds modulating PPAR-gamma | BIOVITRUM AB (SE) | 2003-05-01 | — | — | US | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003005025-A1 | METHODS FOR IDENTIFYING COMPOUNDS MODULATING THE ACTIVITY OF PPAR-GAMMA | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082631-A1 | Compounds modulating PPAR-gamma | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885KDM4E 2272/4885 |
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885KDM4E 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.